•  
  •  
 

Abstract

The general formula of new complexes [M2(BDS)Cl4] are resulting from the reaction of a new ligand [N1, N4- bis (1H- benzo [d] imidazol- 2- yl) -N1, N4 -bis(4-(dimethyl amino) benzyl) succinimide] (BDS) with metal ions M(II) = Cd, Co, Hg, Cu and Ni. This ligand was derived from the reaction of the three substances 4-(Dimethyl amino) benzaldehyde, 2-amino benzimidazole, and succinyl chloride. The compounds are characterized by FT-IR, NMR, UV-Vis and Mass spectroscopy. The serine protease SplB of Staphylococcus aureus and the A chain of Rhomboid-protease-GLPG of Escherichia coli were chosen to study the binding strength of the ligand and the copper complex prepared by molecular docking method. The gold nano-[Cu2(BDS)Cl4] was also prepared from mixing the copper complex solution with the gold nano solution, and the diagnosis was carried out using different methods, including FTIR, UV-Vis and SEM. The inhibition ability of the prepared compounds, including the nanocomplex, was tested against two types of selected bacteria (G-) Escherichia coli & (G+) Staphylococcus aureus, where the results showed that the ability of the nanocomplex to inhibit both types of bacteria was greater than the ligand and the free copper complex. The free copper complex and the nanocomplex were studied to inhibit human lung adenocarcinoma cell line (A549) and compare it with normal cell line rat embryonic fibroblasts (REF). The results showed a high ability of the nanocomplex to inhibit cancer cells, and this confirms the possibility of using it as an anticancer in the future.

Keywords

4-(dimethylamino)benzaldehyde, Cell Line (A549), Gold Nano, Molecular Docking, Nanoparticles

Subject Area

Chemistry

Article Type

Article

First Page

1085

Last Page

1101

Creative Commons License

Creative Commons Attribution 4.0 International License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Download

Share

COinS